Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Change in Accured Expenses (2016 - 2025)

Spero Therapeutics' Change in Accured Expenses history spans 10 years, with the latest figure at -$2.2 million for Q4 2025.

  • For Q4 2025, Change in Accured Expenses fell 193.11% year-over-year to -$2.2 million; the TTM value through Dec 2025 reached -$12.1 million, down 208.77%, while the annual FY2025 figure was -$12.1 million, 208.77% down from the prior year.
  • Change in Accured Expenses reached -$2.2 million in Q4 2025 per SPRO's latest filing, down from $1.1 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $5.3 million in Q3 2024 to a low of -$9.5 million in Q1 2025.
  • Average Change in Accured Expenses over 5 years is -$333150.0, with a median of -$58500.0 recorded in 2023.
  • The largest YoY upside for Change in Accured Expenses was 40033.33% in 2024 against a maximum downside of 960.36% in 2024.
  • A 5-year view of Change in Accured Expenses shows it stood at $5.3 million in 2021, then crashed by 83.38% to $880000.0 in 2022, then tumbled by 100.68% to -$6000.0 in 2023, then skyrocketed by 40033.33% to $2.4 million in 2024, then crashed by 193.11% to -$2.2 million in 2025.
  • Per Business Quant, the three most recent readings for SPRO's Change in Accured Expenses are -$2.2 million (Q4 2025), $1.1 million (Q3 2025), and -$1.5 million (Q2 2025).